BioSpace News Archive

Business

Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2022 Financial Results on February 7, 2023

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the fourth quarter and fiscal 2022 after the close of trading on Tuesday, February 7.

January 10, 2023
·
1 min read
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

SAB Biotherapeutics today announced the successful completion of an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic as a way to prevent and/or delay onset and progression of type 1 diabetes (T1D) and potentially other T-cell mediated autoimmune diseases.

January 10, 2023
·
5 min read
Business

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

Akero Therapeutics, Inc. today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy.

January 10, 2023
·
6 min read
BioMidwest

Geneoscopy’s Noninvasive Colorectal Cancer Screening Test Demonstrates High Sensitivity and Specificity in Large Pivotal Clinical Trial

Geneoscopy Inc. today announced favorable results from the CRC-PREVENT trial – a pivotal clinical trial evaluating the efficacy of its noninvasive, stool-based, at-home diagnostic screening test to detect colorectal cancer (CRC) and advanced adenomas (AA) in average-risk individuals

January 10, 2023
·
8 min read
Biotech Beach

Cardiff Oncology to Present at B. Riley Securities’ 3rd Annual Oncology Conference

Cardiff Oncology, Inc. today announced that company management will participate in a fireside chat at B. Riley Securities’ 3rd Annual Oncology Conference, which is taking place virtually from January 18 – 19, 2023.

January 10, 2023
·
1 min read
Deals

BIOLASE INC. ANNOUNCES PRICING OF APPROXIMATELY $9.75 MILLION UNDERWRITTEN PUBLIC OFFERING

BIOLASE, Inc. today announced the pricing of an underwritten public offering consisting of 16,453,569 shares of its common stock and pre-funded warrants to purchase 11,403,571 shares of common stock at a public offering price of $0.35 per share.

January 10, 2023
·
4 min read
Pharm Country

Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex® 1 Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.

January 10, 2023
·
2 min read
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Cyclo Therapeutics, Inc. today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 11:00 AM ET.

January 10, 2023
·
1 min read
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients

Aytu RxConnect Providing Access Relief to Patients Amid Ongoing Generic Adderall® Supply Disruption.

January 10, 2023
·
9 min read
Genetown

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)

Pieris Pharmaceuticals, Inc. today announced that the Company has achieved a $5 million milestone from Seagen.

January 10, 2023
·
4 min read